Search Results - "Shukla, Navika D"

Functional screening of amplification outlier oncogenes in organoid models of early tumorigenesis by Salahudeen, Ameen A., Seoane, Jose A., Yuki, Kanako, Mah, Amanda T., Smith, Amber R., Kolahi, Kevin, De la O, Sean M., Hart, Daniel J., Ding, Jie, Ma, Zhicheng, Barkal, Sammy A., Shukla, Navika D., Zhang, Chuck H., Cantrell, Michael A., Batish, Arpit, Usui, Tatsuya, Root, David E., Hahn, William C., Curtis, Christina, Kuo, Calvin J.

“…Somatic copy number gains are pervasive across cancer types, yet their roles in oncogenesis are insufficiently evaluated. This inadequacy is partly due to copy…”
Get full text

Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford by Abrha, Aser, Shukla, Navika D, Hodan, Rachel, Longacre, Teri, Raghavan, Shyam, Pritchard, Colin C, Fisher, George, Ford, James, Haraldsdottir, Sigurdis

“…In light of recent Food and Drug Administration (FDA) approval of immune checkpoint inhibitors for mismatch repair deficient (dMMR) malignancies, identifying…”
Get full text

Nectin-1-specific entry of herpes simplex virus 1 is sufficient for infection of the cornea and viral spread to the trigeminal ganglia by Shukla, Navika D, Tiwari, Vaibhav, Valyi-Nagy, Tibor

“…Primary and recurrent infections of the cornea by herpes simplex virus 1 (HSV-1) are important causes of eye disease. Three unrelated classes of glycoprotein D…”
Get full text

Laser interstitial thermal therapy for the treatment of epilepsy: evidence to date by Shukla, Navika D, Ho, Allen L, Pendharkar, Arjun V, Sussman, Eric S, Halpern, Casey H

“…Medically intractable epilepsy is associated with increased morbidity and mortality. For those with focal epilepsy and correlated electrophysiological or…”
Get full text

Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas by Shukla, Navika D., Schroers-Martin, Joseph G., Sworder, Brian J., Kathuria, Karan Raj, Alig, Stefan K., Frank, Matthew J., Miklos, David B., Coutre, Steven, Diehn, Maximilian, Khodadoust, Michael S., Roschewski, Mark, Kurtz, David M., Alizadeh, Ash A.

Get full text

Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy by Shukla, Navika D., Salahudeen, Ameen A., Taylor, Gregory A., Ramalingam, Suresh S., Vokes, Everett E., Goss, Glenwood D., Decker, Roy H., Kelly, Karen, Scagliotti, Giorgio V., Mok, Tony S., Wakelee, Heather A.

“…Cancer cooperative groups have historically played a critical role in the advancement of non–small-cell lung cancer therapy. Representatives from cooperative…”
Get full text

Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS by Shukla, Navika D., Schroers-Martin, Joseph, Kathuria, Karan R., Sworder, Brian, Alig, Stefan K., Frank, Matthew J, Miklos, David B., Coutre, Steven, Diehn, Maximilian, Khodadoust, Michael S., Roschewski, Mark, Kurtz, David M., Alizadeh, Ash A.

Get full text

Measurable Residual Disease Conversion Rate with Consolidation Chemotherapy in Acute Myeloid Leukemia by Gaut, Daria, Oliai, Caspian, Boiarsky, Jonathan, Zhang, Shiliang, Azenkot, Tali, Kennedy, Vanessa E., Khanna, Vishesh, Olmedo Gutierrez, Karla, Shukla, Navika D., Moskoff, Benjamin, Patel, Anand Ashwin, Jeyakumar, Deepa, Mannis, Gabriel N., Logan, Aaron C., Jonas, Brian A., Schiller, Gary J.

Get full text

Abstract B30: Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer by Shukla, Navika D., Salahudeen, Ameen A., Padda, Sukhmani K., Neal, Joel W., Wakelee, Heather A., Kuo, Calvin J.

“…Abstract Background: Targeted therapies against specific driver mutations of cancer progression have been used to improve survival of lung adenocarcinoma…”
Get full text

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas by Sworder, Brian, Kurtz, David M., Alig, Stefan K., Frank, Matthew J, Shukla, Navika D., Garofalo, Andrea, Macaulay, Charles, Shahrokh Esfahani, Mohammad, Olsen, Mari, Hamilton, James, Hosoya, Hitomi, Hamilton, Mark P, Spiegel, Jay Y., Baird, John H., Carleton, Mia, Craig, Alexander F.M., Younes, Sheren F., Sahaf, Bita, Sheybani, Natasha, Schroers-Martin, Joseph, Liu, Chih Long, Oak, Jean S, Jin, Michael C., Beygi, Sara, Hüttmann, Andreas, Hanoun, Christine, Dührsen, Ulrich, Westin, Jason, Khodadoust, Michael S., Natkunam, Yasodha, Majzner, Robbie G., Mackall, Crystal L., Diehn, Maximilian, Miklos, David B., Alizadeh, Ash A.

Get full text

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions by Major, Ajay, Yu, Jovian, Shukla, Navika D., Treitman, Rachel, Kamdar, Manali K., Haverkos, Bradley M., Godfrey, James, Babcook, Melissa A., Voorhees, Timothy J., Carlson, Sophie G, Gaut, Daria, Oliai, Caspian, Romancik, Jason T., Winter, Allison, Hill, Brian T., Bansal, Radhika, Villasboas, Jose C., Nizamuddin, Imran A., Karmali, Reem, Fitzgerald, Lindsey A., Stephens, Deborah M., Pophali, Priyanka A., Trabolsi, Asaad, Schatz, Jonathan H., Hu, Marie, Bachanova, Veronika, Slade, Michael J, Singh, Nathan, Ahmed, Nausheen, McGuirk, Joseph P., Bishop, Michael R., Riedell, Peter A., Kline, Justin

Get full text

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA) by Shukla, Navika D, Craig, Alexander F.M., Sworder, Brian, Kurtz, David M., Macaulay, Charles, Garofalo, Andrea, Frank, Matthew J., Alig, Stefan, Duran, George, Kim, Youn H., Zehnder, James, Mackall, Crystal L., Miklos, David B., Diehn, Maximilian, Khodadoust, Michael S., Alizadeh, Ash A.

“…Background: Characterization of T-cell receptor (TCR) diversity and dynamics is increasingly critical to understanding therapeutic immune responses targeting…”
Get full text